[CAS NO. 1847461-43-1] Mobocertinib (TAK788)
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [1847461-43-1]
Catalog
SLK-S6813
Brand
Selleck
CAS
1847461-43-1
DESCRIPTION [1847461-43-1]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 585.70 |
| Molecular Formula | C32H39N7O4 |
| SMILES | O=C(C1=CN=C(NC2=CC(NC(C=C)=O)=C(N(CCN(C)C)C)C=C2OC)N=C1C3=CN(C)C4=C3C=CC=C4)OC(C)C |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7074 mL | 8.5368 mL | 17.0736 mL |
| 5 mM | 0.3415 mL | 1.7074 mL | 3.4147 mL |
| 10 mM | 0.1707 mL | 0.8537 mL | 1.7074 mL |
| 50 mM | - | - | - |
Description
Mobocertinib (TAK788, AP32788), an investigational TKI, is a potent, selective preclinical inhibitor of and mutations. Mobocertinib (TAK788) is an antineoplastic agent.
In vitro
Mobocertinib (TAK-788), a novel irreversible EGFR TKI, is specifically designed to potently inhibit oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib inhibits viability of various ex20ins-driven cell lines more potently than approved EGFR TKIs.
References
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.